Why the study?
Does subhypotensive dosing of ramipril provide cardioprotective effects independent of blood pressure reduction in animal models of hypertrophy and ischemia?
Does subhypotensive dosing of ramipril provide cardioprotective effects independent of blood pressure reduction in animal models of hypertrophy and ischemia?
ACE inhibitors provide direct cardioprotective effects, including prevention of hypertrophy and reduction of infarct size, independent of their blood pressure-lowering effects, likely mediated by local kinins.
No takes yet. Share an insight, caveat, or question.
Subhypotensive ramipril effects in animals do not support clinical dosing changes; leaves open translation of BP-independent cardioprotection to humans.
Schölkens et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: